SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

FuboTV, Inc. is a consumer-first live TV streaming company with the mission of delivering premium sports, news and entertainment programming that offers greater choice, flexibility and value. The company was founded by David Gandler, Alberto Horihuela Suarez, and Sung Ho Choi on February 20, 2009 and is headquartered in New York, NY.

fuboTV Inc - Ordinary Shares - Class A

fuboTV Inc

FuboTV is currently seeing heightened community debate following an officially scheduled reverse stock split, with retail investors questioning the company's valuation and long-term viability in the competitive streaming sector. While some participants anticipate a short squeeze or a potential rebound on the low float, many are voicing frustration over management's performance and the lack of clear, actionable catalysts to drive a meaningful recovery.

Karyopharm Therapeutics, Inc. is a commercial-stage pharmaceutical company, which engages in the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. The company was founded by Joseph Araujo, Ronald A. DePinho, Pamela A, Silver, Giulio Draetta, Michael G. Kauffman, and Sharon Shacham on December 22, 2008, and is headquartered in Newton, MA.

Karyopharm Therapeutics Inc

Karyopharm Therapeutics is currently seeing intense investor scrutiny and volatility as the community remains deeply divided over the company's financial stability, impending trial readouts, and the performance of current leadership. Investors are actively debating the potential for a Phase 3 SENTRY trial success versus the significant risks posed by high debt levels and the necessity for strategic financing to extend operations.

Far below the surface, where light no longer reaches and noise collapses into silence, the Sperm Whale endures.  It does not rely on speed or spectacle. It survives through mass, intelligence, and absolute awareness of its surroundings.  This project is shaped by the same principle — strength formed under pressure, movement guided by understanding, and conviction built where others cannot remain.  While the surface reacts, the deep decides.

The Sperm Whale

The meme coin SPERMWHALE is attracting attention from speculative traders due to its rapid, high-percentage price moves and low market capitalization, sparking intense debate over whether it represents a legitimate growth opportunity or a classic pump-and-dump scheme. While proponents highlight early accumulation patterns and potential for massive gains, critics emphasize the high concentration of supply among top holders and the lack of fundamental utility, urging others to be cautious of potential rug pulls.

BioCryst Pharmaceuticals, Inc. is a biotechnology company. It engages in the provision of structure-guided drug design with the goal of developing oral small-molecule and protein therapeutics to target difficult-to-treat rare diseases. The company was founded by William M. Spencer III, Charles E. Bugg, and John A. Montgomery in 1986 and is headquartered in Durham, NC.

Biocryst Pharmaceuticals Inc.

BioCryst Pharmaceuticals is seeing significant volatility and increased trading volume following unconfirmed market rumors regarding potential M&A activity. The community is actively debating the credibility of these buyout reports, with many long-term shareholders expressing optimism for a potential exit while others remain cautious of historical patterns involving speculative biotech price swings.

Cantor Equity Partners II, Inc. is a blank check company. The company was founded on November 11, 2020 and is headquartered in New York, NY

Cantor Equity Partners II Inc. - Ordinary Shares - Class A

Cantor Equity Partners II Inc

Investors are closely monitoring CEPT as it approaches its merger with Securitize, a leading infrastructure provider in the rapidly expanding real-world asset tokenization space. The community is actively debating the stock's potential as a pure-play opportunity, highlighting strong institutional backing from major firms like BlackRock and recent positive reports from analyst research firms.

Concentrix Corp. engages in the provision of customer experience solutions and technology. The company was founded in 1973 and is headquartered in Newark, CA.

Concentrix Corp.

Concentrix Corporation

Concentrix is seeing intense investor focus as the stock reacts to mixed Q1 results and the announced $4.8 billion merger with Webhelp. While the community is actively debating the implications of the deal on long-term growth and debt levels, traders are closely tracking the stock's volatility and its potential to capture synergy-driven value.

Li Auto, Inc. engages in the design, development, manufacture, and sale of premium smart electric vehicles. Its products include Li MEGA, a high-tech flagship family MPV, Li L9, a six-seat flagship family SUV, and Li L8, a six-seat premium family SUV, and Li L7, a five-seat flagship family SUV. The firm also offers in-house development efforts on its proprietary range extension system, next-generation electric vehicle technology, and smart vehicle solutions. The company was founded by Xiang Li in April 2015 and is headquartered in Beijing, China.

Li Auto Inc - ADR

Li Auto is under intense scrutiny after announcing a $1B share repurchase program, sparking polarized debate among investors regarding its long-term viability versus rivals like NIO. Community sentiment is deeply divided, with some betting on a rebound supported by the buyback and potential technological pivots, while vocal critics point to shifting delivery momentum, margin pressures, and intense competition from peers as reasons to divest.

Core & Main, Inc. is a specialty distributor focused on water, wastewater, storm drainage and fire protection products, and related services. The company provides infrastructure solutions to municipalities, private water companies and professional contractors across municipal, non-residential, and residential end markets, nationwide. The company was founded in 1874 and is headquartered in St. Louis, MO.

Core & Main Inc - Ordinary Shares Class A

Core & Main Inc

Core & Main is seeing active engagement as investors digest the company's latest quarterly earnings, which showed solid sales growth and raised full-year guidance despite broader macroeconomic headwinds. The community is focused on the firm's acquisition-heavy growth strategy and its role as a key player in U.S. water infrastructure, with many debating the impact of ongoing share repurchases on long-term value.

Smithfield Foods, Inc. operates as a meat-processing company. The firm processes and produces pork and hog. Its brands include Smithfield, Eckrich, Nathan's Famous, Farmland, and Armour. The company was founded by Joseph Williamson Luter, Sr. and Joseph Williamson Luter, Jr. in 1936 and is headquartered in Smithfield, VA.

Smithfield Foods, Inc.

Smithfield Foods Inc.

Smithfield Foods is trending as investors digest a strong quarterly earnings report that exceeded consensus estimates for both revenue and EPS. Market participants are actively discussing the company's dividend increase, strategic expansion through the acquisition of the Nathans Famous brand, and the impact of evolving USDA rules on meat processing operations.

Merlin, Inc. is an aerospace and defense technology company focused on developing autonomous flight solutions. The company is building an operating system of record for autonomous aviation, with its Merlin Pilot system enabling a wide range of aircraft and mission profiles. Its technology has been validated through hundreds of autonomous flights conducted at test facilities worldwide. The company is headquartered in Boston, MA.

Merlin Inc.

Marlin Business Services Corp.

Marlin (MRLN) is trending as investors react to its recent transition from a SPAC to a Nasdaq-listed entity, with the community actively debating the company's autonomous aviation technology and potential for long-term defense contract scaling. Market sentiment is fueled by speculation around institutional interest and a low-float setup, leading many to compare its growth trajectory to other high-momentum players in the autonomous systems and defense sectors.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Private Client Services LLC Takes $1.99 Million Position in Exelixis, Inc. $EXEL

Private Client Services LLC bought a new stake in Exelixis, Inc. (NASDAQ:EXEL - Free Report) in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The...

Strategic Investment Advisors MI Buys 27,659 Shares of Exelixis, Inc. $EXEL

Strategic Investment Advisors MI lifted its stake in Exelixis, Inc. (NASDAQ:EXEL - Free Report) by 486.6% during the 3rd quarter, according to the company in its most recent disclosure with the...

Here's Why Exelixis (EXEL) is a Strong Value Stock

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

L2 Asset Management LLC Invests $3.36 Million in Exelixis, Inc. $EXEL

L2 Asset Management LLC purchased a new stake in shares of Exelixis, Inc. (NASDAQ:EXEL - Free Report) during the 3rd quarter, according to the company in its most recent 13F filing with the...

Exelixis, Inc. $EXEL Shares Acquired by Clark Capital Management Group Inc.

Clark Capital Management Group Inc. increased its position in shares of Exelixis, Inc. (NASDAQ:EXEL - Free Report) by 14.3% during the third quarter, according to the company in its most recent Form...

Exelixis Highlights Zanzalintinib RCC Trials, Sequencing Debate, and December CRC PDUFA at Leerink

Exelixis (NASDAQ:EXEL) executives and investors spent part of the discussion at a Leerink event focusing on recent renal cell carcinoma (RCC) data, evolving treatment sequencing debates, and the...

Exelixis Highlights CABOMETYX Growth, Zanzalintinib PDUFA and Pipeline Strategy at Barclays Conference

Exelixis (NASDAQ:EXEL) described its current commercial trajectory, late-stage clinical programs, and strategic priorities during a discussion at a Barclays event featuring Senior Vice President of...

Exelixis Highlights $2.4B 2026 Outlook, Cabometyx Momentum and Zanzalintinib Catalysts at Conference

Exelixis (NASDAQ:EXEL) detailed its commercial momentum for cabozantinib and outlined key upcoming clinical catalysts for zanzalintinib during a discussion at the Citizens Life Sciences Conference...

Capital Impact Advisors LLC Boosts Stock Position in Exelixis, Inc. $EXEL

Capital Impact Advisors LLC lifted its stake in Exelixis, Inc. (NASDAQ:EXEL - Free Report) by 15.2% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange...

Exelixis, Inc. $EXEL Stake Raised by South Street Advisors LLC

South Street Advisors LLC raised its holdings in Exelixis, Inc. (NASDAQ:EXEL - Free Report) by 127.9% in the third quarter, according to its most recent 13F filing with the Securities and Exchange...

Exelixis, Inc. is an oncology company, which focuses on discovering, developing, and commercialization of new medicines for difficult-to-treat cancers. Its products include cabometyx, cometriq, and cotellic. The company was founded by Stelios Papadopoulos on November 15, 1994, and is headquartered in Alameda, CA.

Current Price	$41.41
Prev Close	$41.27
Open	$41.80
Dividend Yield	0.00%
50-Day Moving Average	$42.99
Beta	0.46
Avg. Volume	2.89M
PE Ratio	14.88

52-Week High	$49.62
52-Week Low	$32.38
Market Capitalization	$10.75B
EPS (Annual)	$2.78
Price to Book	5.03
Revenue Per Employee	$2.15M

EXEL
Exelixis Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest EXEL News

EXELExelixis Inc